China healthcare out-licensing activity: Merck’s USD400mn upfront deal signals rising overseas demand for Chinese biotech assets
Nomura highlights Merck’s in-licensing of SciBrunch’s pre-clinical KRAS G12D inhibitor as a record upfront-payment transaction for such an asset. It sees the deal, alongside Eli Lilly’s recent agreement with Innovent, as evidence that US buyers are increasing their commitment to Chinese healthcare assets.
Summary
Nomura highlights Merck’s in-licensing of SciBrunch’s pre-clinical KRAS G12D inhibitor as a record upfront-payment transaction for such an asset. It sees the deal, alongside Eli Lilly’s recent agreement with Innovent, as evidence that US buyers are increasing their commitment to Chinese healthcare assets.
- Merck agreed to pay USD400mn upfront for global exclusive rights to SciBrunch’s pre-clinical SPR2015.
- Total milestone payments could reach USD2.13bn.
- Pharmcube characterized the upfront payment as historic for a pre-clinical asset.
- Nomura observes a recent acceleration in US in-licensing activity in China.
- Eli Lilly separately announced USD100mn upfront and near-term payments, plus up to about USD3.25bn in milestones, in its agreement with Innovent.
Report Interpretation
Overview
This China healthcare event commentary examines Merck’s licensing agreement for a Shanghai-founded biotech’s pre-clinical KRAS G12D inhibitor. Nomura views the transaction as a strong signal of overseas buyers’ growing willingness to pay for innovative Chinese assets and notes a recent pickup in US-China life-science collaborations.
Core views
Merck announced on the evening of 28 September, Hong Kong time, that it would in-license SPR2015, a pre-clinical KRAS G12D (ON) inhibitor, from unlisted SciBrunch Therapeutics. SciBrunch was founded in Shanghai only two years earlier. Merck obtained global exclusive rights in exchange for USD400mn upfront and milestone payments totaling USD2.13bn. Nomura cites Pharmcube’s characterization of the USD400mn upfront component as historic for a pre-clinical asset, making the transaction the central evidence for its view that overseas buyers place substantial value on Chinese biotech assets. Nomura attributes the appeal of Chinese assets to their novelty and/or potential for higher efficacy. It argues that cash-rich multinational companies are increasing their commitment, with purchase prices serving as evidence of that willingness. The report also observes that US companies have recently accelerated in-licensing in China following what it describes as positive geopolitical developments. However, it qualifies this interpretation: negotiations take months, so the timing may be coincidental. It further notes that activity had slowed somewhat in May, when the cross-Pacific collaboration environment was less favorable. The Merck-SciBrunch transaction is presented alongside Eli Lilly’s 24 September agreement with Innovent. Under that deal, Eli Lilly announced USD100mn of upfront and near-term payments and up to approximately USD3.25bn in milestone payments. Together, these transactions support Nomura’s observation of renewed cross-Pacific licensing activity and stronger overseas buyer interest in Chinese healthcare innovation.
Analysis framework
Nomura uses recent licensing transactions as evidence of buyer demand for Chinese biotech assets. It compares the size and development stage of the Merck-SciBrunch deal with another recent Eli Lilly-Innovent agreement, then relates the observed pace of activity to the cross-Pacific geopolitical collaboration environment while explicitly acknowledging uncertainty about causation.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- SciBrunch TherapeuticsLicensor of SPR2015 to Merck under a global exclusive-rights agreement.
- Strengths
- Shanghai-founded biotech with a pre-clinical KRAS G12D (ON) inhibitor that attracted USD400mn upfront consideration.
- Weaknesses
- The asset is pre-clinical.
- Comparison
- The upfront payment was described by Pharmcube as historic for a pre-clinical asset.
- Merck (MRK US)Licensee acquiring global exclusive rights to SPR2015 from SciBrunch.
- Comparison
- Its transaction is compared with Eli Lilly’s recent licensing agreement with Innovent.
- Innovent (9969 HK/688428 CH)Counterparty to Eli Lilly’s recent licensing agreement.
- Strengths
- Agreement included USD100mn of upfront and near-term payments and up to c.USD3.25bn in milestones.
- Comparison
- Cited as additional evidence of recent US in-licensing activity in China.
Key data
- Merck upfront payment to SciBrunchUSD400mnUpfront consideration for global exclusive rights to pre-clinical SPR2015; described by Pharmcube as historic for a pre-clinical asset.
- Merck milestone payments to SciBrunchUSD2.13bnTotal potential milestone payments under the global licensing agreement.
- Eli Lilly upfront and near-term payments to InnoventUSD100mnAnnounced on 24 September.
- Eli Lilly potential milestone payments to Innoventc.USD3.25bnMaximum stated milestone payments under the agreement.
Impact & implications
The report interprets the size of the Merck-SciBrunch transaction and the recent Eli Lilly-Innovent agreement as evidence that multinational buyers are placing greater value on Chinese healthcare innovation. It also suggests that a more constructive geopolitical backdrop may be supporting cross-Pacific licensing, while cautioning that deal timing alone does not establish causation.